Please assess the completion status of the following clinical trial:

Trial Title: Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subject must:~* Provide written informed consent.~* Have a Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) diagnosis of opioid dependence.~* Be male or female, 18 to 65 years of age, inclusive.~* If female, have a negative pregnancy test during screening and agree to use an acceptable method of birth control.~Exclusion Criteria:~Subjects must not:~* Have participated in an experimental drug or device study within the last 30 days.~* Be currently (past 30 days from start of screening) engaged in opioid agonist, opioid partial agonist, or opioid antagonist treatment.~* If female, be breast feeding or lactating.~* Have any medical condition that in the opinion of the physician investigator would preclude the subject from completing the study.~* Have any clinically significant non-substance use psychiatric disorder (e.g., schizophrenia).~* Have current suicidal ideation.~* Have a Mini Mental Status Exam score less than 24.~* Have physical dependence on alcohol.~* Have physical dependence on sedative-hypnotics.~* Have active aphthous stomatitis.~* Have active oral herpes.~* Need on-going prescription medications that interact with the P450 3A4 (a member of the cytochrome P450 superfamily of enzymes) system.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Buprenorphine soluble film (Type: EXPERIMENTAL): Day 1: Buprenorphine soluble film administered at a dose of 4 mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2-5: Buprenorphine soluble film administered at a dose of 16 mg to 24 mg once per day, plus placebo. Dosing occurred at 0900 hours.
- Buprenorphine/naloxone soluble film (Type: EXPERIMENTAL): Day 1: Buprenorphine/naloxone soluble film administered at a dose of 4mg/1mg 3 times per day, plus placebo. Dosing occurred at 0900, 1100, and 2000 hours.~Days 2 to 5: Buprenorphine/naloxone soluble film administered at a dose of 16mg/4 mg to 24 mg/6 mg once per day, plus placebo. Dosing occurred at 0900 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).